Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
复制标题
抗表皮生长因子受体治疗联合诱导化疗治疗局部晚期鼻咽癌
DOI：
10.1111/cas.13589
复制
发表时间：
2018-05
期刊：
影响因子：
5.7
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Peng H;Tang LL;Liu X;Chen L;Li WF;Mao YP;Zhang Y;Liu LZ;Tian L;Guo Y;Sun Y;Ma J
Little is known about the efficacy and toxicity of anti‐epidermal growth factor receptor therapy concurrently with induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). The present study aimed to address this question. We identified 2848 patients with newly diagnosed LA‐NPC receiving IC between January 2012 and May 2015. The propensity score matching (PSM) method was used to balance various factors and to match patients. Survival outcomes and toxicities between different groups were compared. In total, 596 patients were selected at a 1:3 ratio, with 149 in the IC + CTX/NTZ group and 447 in the IC alone group. The 3‐year disease‐free survival, overall survival, distant metastasis‐free survival and locoregional relapse‐free survival rates for IC + CTX/NTZ vs IC alone were 84.3% vs 75.2% (P = .059), 94.0% vs 87.9% (P = .053), 88.0% vs 84.9% (P = .412) and 93.3% vs 88.2% (P = .242). Multivariate analysis established a treatment group (IC vs IC + CTX/NTZ) as a prognostic predictor for DFS (hazard ratio [HR], 1.497; 95% confidence interval [CI], 1.016‐2.206; P = .041) and OS (HR, 1.984; 95%, CI, 1.023‐3.848; P = .043). Grade 3‐4 skin reaction (15.4% vs 0.4%, P < .001) and mucositis (10.1% vs 2.7%, P < .001) were more common in the IC + CTX/NTZ group than that in the IC alone group. Our findings suggested that CTX/NTZ in combination with IC may be a more effective and promising strategy for patients with LA‐NPC treated with intensity‐modulated radiotherapy.
登录
查看更多内容
影响因子：
3.9
作者：
Peng H;Chen L;Zhang J;Li WF;Mao YP;Zhang Y;Liu LZ;Tian L;Lin AH;Sun Y;Ma J
通讯作者：
Ma J
影响因子：
45.3
作者：
Hui, Edwin P.;Ma, Brigette B.;Chan, Anthony T.
通讯作者：
Chan, Anthony T.
DOI：
10.1016/j.ijrobp.2004.03.002
发表时间：
2004-09-01
影响因子：
7
作者：
Lin, JC;Liang, WM;Lin, AC
通讯作者：
Lin, AC
新辅助化疗后同步放化疗与单独同步放化疗治疗局部晚期鼻咽癌：一项 III 期多中心随机对照试验。
影响因子：
8.4
作者：
Cao, Su-Mei;Yang, Qi;Hong, Ming-Huang
通讯作者：
Hong, Ming-Huang
II-IVb 期鼻咽癌同步放化疗联合或不联合抗 EGFR 靶向治疗：大队列和长期随访的回顾性分析
影响因子：
12.4
作者：
You R;Hua YJ;Liu YP;Yang Q;Zhang YN;Li JB;Li CF;Zou X;Yu T;Cao JY;Zhang MX;Jiang R;Sun R;Mo HY;Guo L;Cao KJ;Lin AH;Sun Y;Qian CN;Ma J;Chen MY
通讯作者：
Chen MY